Policy | |
1. % of countries with a current (updated in the last 2 years) essential medicines list (EML) | |
2. % of countries with an EML that includes tracer RMNCH medicinesa | |
3. % of countries with RMNCH tracer medicines in standard treatment guidelines (STGs) | |
4. % of countries where RMNCH tracer medicines in the STG are also on the EMLa | |
5. % of countries with a national policy on the use of community management of pneumonia | |
6. % of countries with a national policy on the use of community management of diarrhea | |
Regulatory | |
7. % of countries where tracer medicines have at least one product registered for use in countrya | |
8. % of countries where quality problems are reported | |
9. % of countries where medicines (including RMNCH medicines) products are routinely sampled for quality testing | |
Procurement | |
10. % of countries where RMNCH commodities are procured centrally a | |
Financing | |
11. % of countries with a costed MNCH plan | |
12. % of countries with fees for services in the public sector | |
13. % of countries with fees for services where women and children under 5 are exempt from paying for RMNCH services or medicines | |
14. % of countries with a policy to provide RMNCH commodities free of charge in public sector a | |
Supply Chain Management | |
15. % of countries with a pull (demand-based) distribution method to health facilities | |
16. % of countries with stock outs of RMNCH tracer products reported at CMS in last 3 yearsa | |
Information systems | |
17. % of countries with a logistics management information system (LMIS) to track stock-level/consumption of medicines (paper, electronic, or mobile) | |
18. % of countries where all tracer RMNCH commodities are included in LMISa |